PDF(Pubmed)
Abstract：
UNASSIGNED: Hyperuricemia and gout are receiving an increasing scientific and medical attention because of their relatively high prevalence and their association with relevant co-morbidities. Recently, it has been suggested that gout patients have an altered gut microbiota. The first objective of this study was to investigate the potential of some Ligilactobacillus salivarius strains to metabolize purine-related metabolites. The second objective was to evaluate the effect of administering a selected potential probiotic strain in individuals with a history of hyperuricemia.
UNASSIGNED: Inosine, guanosine, hypoxanthine, guanine, xanthine, and uric acid were identified and quantified by high-performance liquid chromatography analysis. The uptake and biotransformation of these compounds by a selection of L. salivarius strains were assessed using bacterial whole cells and cell-free extracts, respectively. The efficacy of L. salivarius CECT 30632 to prevent gout was assessed in a pilot randomized controlled clinical trial involving 30 patients with hyperuricemia and a history of recurrent gout episodes. Half of the patients consumed L. salivarius CECT 30632 (9 log10 CFU/day; probiotic group; n = 15) for 6 months while the remaining patients consumed allopurinol (100-300 mg/daily; control group; n = 15) for the same period. The clinical evolution and medical treatment received by the participants were followed, as well as the changes in several blood biochemical parameters.
UNASSIGNED: L. salivarius CECT 30632 was the most efficient strain for inosine (100%), guanosine (100%) and uric acid (50%) conversion and, therefore, it was selected for the pilot clinical trial. In comparison with the control group, administration of L. salivarius CECT 30632 resulted in a significant reduction in the number of gout episodes and in the use of gout-related drugs as well as an improvement in some blood parameters related to oxidative stress, liver damage or metabolic syndrome.
UNASSIGNED: Regular administration of L. salivarius CECT 30632 reduced serum urate levels, the number of gout episodes and the pharmacological therapy required to control both hyperuricemia and gout episodes in individuals with a history of hyperuricemia and suffering from repeated episodes of gout.
UNASSIGNED: Inosine, guanosine, hypoxanthine, guanine, xanthine, and uric acid were identified and quantified by high-performance liquid chromatography analysis. The uptake and biotransformation of these compounds by a selection of L. salivarius strains were assessed using bacterial whole cells and cell-free extracts, respectively. The efficacy of L. salivarius CECT 30632 to prevent gout was assessed in a pilot randomized controlled clinical trial involving 30 patients with hyperuricemia and a history of recurrent gout episodes. Half of the patients consumed L. salivarius CECT 30632 (9 log10 CFU/day; probiotic group; n = 15) for 6 months while the remaining patients consumed allopurinol (100-300 mg/daily; control group; n = 15) for the same period. The clinical evolution and medical treatment received by the participants were followed, as well as the changes in several blood biochemical parameters.
UNASSIGNED: L. salivarius CECT 30632 was the most efficient strain for inosine (100%), guanosine (100%) and uric acid (50%) conversion and, therefore, it was selected for the pilot clinical trial. In comparison with the control group, administration of L. salivarius CECT 30632 resulted in a significant reduction in the number of gout episodes and in the use of gout-related drugs as well as an improvement in some blood parameters related to oxidative stress, liver damage or metabolic syndrome.
UNASSIGNED: Regular administration of L. salivarius CECT 30632 reduced serum urate levels, the number of gout episodes and the pharmacological therapy required to control both hyperuricemia and gout episodes in individuals with a history of hyperuricemia and suffering from repeated episodes of gout.
摘要：
未经证实：高尿酸血症和痛风由于其相对较高的患病率及其与相关的合并症的关联而受到越来越多的科学和医学关注。最近,有人认为痛风患者的肠道微生物群发生了改变。这项研究的第一个目的是研究某些唾液杆菌菌株代谢嘌呤相关代谢物的潜力。第二个目的是评估在具有高尿酸血症病史的个体中施用选定的潜在益生菌菌株的效果。
未经授权：肌苷，鸟苷,次黄嘌呤,鸟嘌呤,黄嘌呤,和尿酸通过高效液相色谱分析进行鉴定和定量。使用细菌全细胞和无细胞提取物评估了通过选择唾液乳杆菌菌株对这些化合物的摄取和生物转化。分别。唾液乳杆菌CECT30632预防痛风的疗效在一项涉及30例高尿酸血症和痛风复发病史患者的随机对照临床试验中进行了评估。一半的患者消耗唾液乳杆菌CECT30632（9log10CFU/天；益生菌组；n=15）6个月，而其余患者消耗别嘌呤醇（100-300mg/天；对照组；n=15）。遵循参与者接受的临床演变和医学治疗，以及几种血液生化指标的变化。
未经批准：L.唾液CECT30632是肌苷最有效的菌株(100%)，鸟苷(100%)和尿酸(50%)的转化率,因此,它被选为试点临床试验。与对照组相比，唾液乳杆菌CECT30632的给药导致痛风发作次数和痛风相关药物的使用显着减少，以及一些与氧化应激相关的血液参数的改善，肝损害或代谢综合征。
未经授权：定期服用唾液乳杆菌CECT30632可降低血清尿酸水平，在有高尿酸血症病史和反复痛风发作的个体中，痛风发作次数和控制高尿酸血症和痛风发作所需的药物治疗。
未经授权：肌苷，鸟苷,次黄嘌呤,鸟嘌呤,黄嘌呤,和尿酸通过高效液相色谱分析进行鉴定和定量。使用细菌全细胞和无细胞提取物评估了通过选择唾液乳杆菌菌株对这些化合物的摄取和生物转化。分别。唾液乳杆菌CECT30632预防痛风的疗效在一项涉及30例高尿酸血症和痛风复发病史患者的随机对照临床试验中进行了评估。一半的患者消耗唾液乳杆菌CECT30632（9log10CFU/天；益生菌组；n=15）6个月，而其余患者消耗别嘌呤醇（100-300mg/天；对照组；n=15）。遵循参与者接受的临床演变和医学治疗，以及几种血液生化指标的变化。
未经批准：L.唾液CECT30632是肌苷最有效的菌株(100%)，鸟苷(100%)和尿酸(50%)的转化率,因此,它被选为试点临床试验。与对照组相比，唾液乳杆菌CECT30632的给药导致痛风发作次数和痛风相关药物的使用显着减少，以及一些与氧化应激相关的血液参数的改善，肝损害或代谢综合征。
未经授权：定期服用唾液乳杆菌CECT30632可降低血清尿酸水平，在有高尿酸血症病史和反复痛风发作的个体中，痛风发作次数和控制高尿酸血症和痛风发作所需的药物治疗。
